Author: NSV
NorthSea Therapeutics Announces US $40 Million Series B Financing to Complete Phase IIb ICONA study in NASH and to Advance Two Additional SEFAs into the Clinic
Two new US investors; lead investor, venBio Partners and Sofinnova Investments, join syndicate of existing investors Richard Gaster, M.D., Ph.D., Principal at venBio Partners, and Maha Katabi, Ph.D., CFA, Partner at Sofinnova Investments join the Board Proceeds will be used to progress the SEFA development pipeline: Completion of Phase 2b
Read More
EXTEN Technologies and AIC to Provide NVMe-oF Storage Solutions Optimized for Supercomputing
AIC Shark Ultra-High-Performance Storage Target Delivers 80GB/S of Random IOPs in 2U with EXTEN NVMe-oF HyperDynamic Software Austin, November 14, 2019 – AIC and EXTEN® Technologies have partnered to provide a dense and scalable, software-defined NVMe-oF solution with record-breaking performance, advanced management, provisioning, and RAID data protection services. This disaggregated
Read More
NST doses first patient in Phase 2b clinical study of icosabutate in NASH (‘ICONA’)
Naarden, The Netherlands, 25 September 2019 – NorthSea Therapeutics B.V., (‘NST’) a Dutch biotech company developing novel and innovative strategies for the treatment of NASH (Non-alcoholic Steatohepatitis) and other metabolic, inflammatory and fibrotic diseases, today announces dosing of the first patient with icosabutate in a phase 2b dose ranging study (‘ICONA’).
Read More
NorthSea Therapeutics strengthens its management team with the appointment of Mats Blom as CFO
Naarden, The Netherlands, 4 September 2019 – NorthSea Therapeutics B.V., (‘NST’) a Dutch biotech company developing novel and innovative strategies for the treatment of NASH and other metabolic, inflammatory and fibrotic diseases, today announces the appointment of Mats Blom as Chief Financial Officer (CFO). Mr Blom joined NorthSea Therapeutics on 3
Read More
EXTEN® Technologies Wins Flash Memory Summit 2019 Best of Show Award for Most Innovative Enterprise Business Application
Second consecutive Best of Show win for EXTEN Technologies demonstrates the leadership position of its HyperDynamic® storage software Santa Clara, CA, August 8, 2019 –EXTEN Technologies®, Inc. announced that its HyperDynamic NVMe over Fabrics high performance storage software won the Best of Show Business Application Award at the 2019 Flash Memory
Read More
EXTEN® Technologies Announces Version 3.0 of its HyperDynamic® NVMe over Fabrics Storage Software with Enhanced High-Performance Resiliency Features
Austin, TX, August 1, 2019 –EXTEN Technologies®, Inc. announced the availability of the third generation of its award winning HyperDynamic® storage software that brings advanced levels of resiliency, performance and management to demanding data center customers across the globe. EXTEN software is perfect for the extreme levels of performance required by
Read More
AIC and EXTEN Technologies to Provide NVMe-oF Storage Solutions with the Same Ultra-high Performance as Direct Connected NVMe
Taipei, Taiwan, May 23, 2019 – AIC and EXTEN Technologies have partnered to provide a complete NVMe-oF target solution using a cost-effective FBOF platform running Broadcom PS1100R Stingray 100G SmartNIC with EXTEN HyperDynamic Software. The AIC J2024-04 platform supports twice the PCIe bandwidth of a typical 2U server, allowing quad
Read More
TherOx Receives FDA Approval for the First Heart Attack Treatment Since PCI to Reduce Infarct Size
View Full Press Release >>
Read More
Oppilan Pharma Initiates Phase 1 Clinical Study with OPL-002
A novel S1P1 modulator for the treatment of inflammatory bowel disease ENCINITAS, California and Cambridge, United Kingdom, January 7, 2019 – Oppilan Pharma Ltd, a clinical-stage biopharmaceutical company focused on developing novel small molecule therapeutics for the treatment of autoimmune diseases, today announced that it has completed dosing of the
Read More
Icosabutate latest data shows direct and potent anti-fibrotic effect in both differentiated rodent NASH models and human stellate cells
Results to be presented at the AASLD congress 2018, 9-13 November In a biopsy-confirmed fibrotic ob/ob NASH mouse model, icosabutate reduced hepatic fibrosis in association with a 45% decrease in myofibroblast content in pre- versus post-treatment liver biopsies In a CDAA NASH mouse model, icosabutate reduced fibrosis levels to baseline
Read More
Escalier Doses First Patient with ESR-114 and Announces Clinical Advisory Board
Commences study to assess novel RORγt inhibitor for the treatment of psoriasis Recruits key opinion leaders to guide clinical development of its RORγt programs NIJMEGEN, The Netherlands and Encinitas, California, August 13, 2018 – Escalier Biosciences, BV, a privately held biopharmaceutical company and a leader in the field of immunology,
Read More